Travis Steed
Stock Analyst at B of A Securities
(2.77)
# 2,015
Out of 5,072 analysts
87
Total ratings
44.93%
Success rate
6.66%
Average return
Main Sectors:
Stocks Rated by Travis Steed
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| MASI Masimo | Initiates: Neutral | $162 | $142.48 | +13.70% | 1 | Nov 17, 2025 | |
| BDX Becton, Dickinson and Company | Maintains: Overweight | $279 → $261 | $194.02 | +34.52% | 9 | Apr 7, 2025 | |
| PEN Penumbra | Initiates: Buy | $320 | $293.17 | +9.15% | 1 | Mar 14, 2025 | |
| ABT Abbott Laboratories | Maintains: Buy | $133 → $150 | $128.90 | +16.37% | 5 | Mar 10, 2025 | |
| SOLV Solventum | Maintains: Neutral | $80 → $85 | $85.26 | -0.30% | 3 | Feb 26, 2025 | |
| EW Edwards Lifesciences | Upgrades: Buy | $82 → $90 | $86.67 | +3.84% | 4 | Dec 16, 2024 | |
| CBLL CeriBell | Initiates: Buy | $32 | $16.97 | +88.57% | 1 | Nov 5, 2024 | |
| BAX Baxter International | Maintains: Neutral | $42 → $45 | $18.74 | +140.13% | 5 | Mar 5, 2024 | |
| OM Outset Medical | Downgrades: Underperform | $480 → $45 | $4.56 | +886.84% | 1 | Oct 13, 2023 | |
| SYK Stryker | Upgrades: Buy | $315 | $371.18 | -15.14% | 5 | Sep 5, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $365 → $295 | $327.19 | -9.84% | 3 | Aug 24, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $16 | $28.65 | -44.15% | 5 | Aug 22, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | $45 → $33 | $21.03 | +56.96% | 2 | May 5, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Neutral | $120 → $160 | $97.52 | +64.07% | 11 | May 3, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $300 → $315 | $573.48 | -45.07% | 2 | Apr 19, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | $8 | $1.62 | +393.83% | 1 | Jan 3, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Underperform | $25 | $12.76 | +96.00% | 1 | Jun 21, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $120 → $85 | $14.25 | +496.49% | 3 | Oct 13, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $125 | $63.47 | +96.94% | 7 | May 25, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Equal-Weight | $145 | $105.33 | +37.66% | 1 | May 25, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $51 | $101.58 | -49.79% | 9 | May 25, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $175 | $43.42 | +303.04% | 4 | May 25, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $59 → $54 | $13.04 | +314.11% | 2 | Nov 1, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $22 | $58.87 | -62.63% | 1 | Jul 17, 2017 |
Masimo
Nov 17, 2025
Initiates: Neutral
Price Target: $162
Current: $142.48
Upside: +13.70%
Becton, Dickinson and Company
Apr 7, 2025
Maintains: Overweight
Price Target: $279 → $261
Current: $194.02
Upside: +34.52%
Penumbra
Mar 14, 2025
Initiates: Buy
Price Target: $320
Current: $293.17
Upside: +9.15%
Abbott Laboratories
Mar 10, 2025
Maintains: Buy
Price Target: $133 → $150
Current: $128.90
Upside: +16.37%
Solventum
Feb 26, 2025
Maintains: Neutral
Price Target: $80 → $85
Current: $85.26
Upside: -0.30%
Edwards Lifesciences
Dec 16, 2024
Upgrades: Buy
Price Target: $82 → $90
Current: $86.67
Upside: +3.84%
CeriBell
Nov 5, 2024
Initiates: Buy
Price Target: $32
Current: $16.97
Upside: +88.57%
Baxter International
Mar 5, 2024
Maintains: Neutral
Price Target: $42 → $45
Current: $18.74
Upside: +140.13%
Outset Medical
Oct 13, 2023
Downgrades: Underperform
Price Target: $480 → $45
Current: $4.56
Upside: +886.84%
Stryker
Sep 5, 2023
Upgrades: Buy
Price Target: $315
Current: $371.18
Upside: -15.14%
Aug 24, 2023
Maintains: Buy
Price Target: $365 → $295
Current: $327.19
Upside: -9.84%
Aug 22, 2023
Reiterates: Overweight
Price Target: $16
Current: $28.65
Upside: -44.15%
May 5, 2023
Downgrades: Underperform
Price Target: $45 → $33
Current: $21.03
Upside: +56.96%
May 3, 2023
Upgrades: Neutral
Price Target: $120 → $160
Current: $97.52
Upside: +64.07%
Apr 19, 2023
Maintains: Buy
Price Target: $300 → $315
Current: $573.48
Upside: -45.07%
Jan 3, 2023
Downgrades: Underperform
Price Target: $8
Current: $1.62
Upside: +393.83%
Jun 21, 2022
Initiates: Underperform
Price Target: $25
Current: $12.76
Upside: +96.00%
Oct 13, 2021
Maintains: Overweight
Price Target: $120 → $85
Current: $14.25
Upside: +496.49%
May 25, 2021
Initiates: Overweight
Price Target: $125
Current: $63.47
Upside: +96.94%
May 25, 2021
Initiates: Equal-Weight
Price Target: $145
Current: $105.33
Upside: +37.66%
May 25, 2021
Initiates: Overweight
Price Target: $51
Current: $101.58
Upside: -49.79%
May 25, 2021
Initiates: Overweight
Price Target: $175
Current: $43.42
Upside: +303.04%
Nov 1, 2018
Maintains: Neutral
Price Target: $59 → $54
Current: $13.04
Upside: +314.11%
Jul 17, 2017
Initiates: Overweight
Price Target: $22
Current: $58.87
Upside: -62.63%